The precise mechanisms driving poor exercise tolerance in patients with fibrotic interstitial lung diseases (fibrotic ILDs) showing a severe impairment in single-breath lung diffusing capacity for carbon monoxide (DLCO < 40% predicted) are not fully understood. Rather than only reflecting impaired O2 transfer, a severely impaired DLCO may signal deranged integrative physiologic adjustments to exercise that jointly increase the burden of exertional symptoms in fibrotic ILD.
METHODS:
Sixty-seven subjects (46 with idiopathic pulmonary fibrosis, 24 showing DLCO < 40%) and 22 controls underwent pulmonary function tests and an incremental cardiopulmonary exercise test with serial measurements of operating lung volumes and 0–10 Borg dyspnea and leg discomfort scores.
RESULTS:
Subjects from the DLCO < 40% group showed lower spirometric values, more severe restriction, and lower alveolar volume and transfer coefficient compared to controls and participants with less impaired DLCO (P < .05). Peak work rate was ∼45% (vs controls) and ∼20% (vs DLCO > 40%) lower in the former group, being associated with lower (and flatter) O2 pulse, an earlier lactate (anaerobic) threshold, heightened submaximal ventilation, and lower SpO2. Moreover, critically high inspiratory constrains were reached at lower exercise intensities in the DLCO < 40% group (P < .05). In association with the greatest leg discomfort scores, they reported the highest dyspnea scores at a given work rate. Between-group differences lessened or disappeared when dyspnea intensity was related to indexes of increased demand-capacity imbalance, that is, decreasing submaximal, dynamic ventilatory reserve, and inspiratory reserve volume/total lung capacity (P > .05).
CONCLUSIONS:
A severely reduced DLCO in fibrotic ILD signals multiple interconnected derangements (cardiovascular impairment, an early shift to anaerobic metabolism, excess ventilation, inspiratory constraints, and hypoxemia) that ultimately lead to limiting respiratory (dyspnea) and peripheral (leg discomfort) symptoms. DLCO < 40%, therefore, might help in clinical decision-making to indicate the patient with fibrotic ILD who might derive particular benefit from pharmacologic and non-pharmacologic interventions aimed at lessening these systemic abnormalities.
SwigrisJJ, BrownKK, AbdulqawiR, BuchK, DillingDF, KoschelD, et al. Patients’ perceptions and patient-reported outcomes in progressive fibrosing interstitial lung diseases. Eur Respir Rev, 2018; 27(150):180075.
4.
HollandAE. Exercise limitation in interstitial lung disease - mechanisms, significance, and therapeutic options. Chron Respir Dis, 2010; 7(2):101-111.
5.
ChangJA, CurtisJR, PatrickDL, RaghuG. Assessment of health-related quality of life in patients with interstitial lung disease. Chest, 1999; 116(5):1175-1182.
Molgat-SeonY, SchaefferMR, RyersonCJ, GuenetteJA. Cardiopulmonary exercise testing in patients with interstitial lung disease. Front Physiol, 2020; 11:832.
8.
PellegrinoR, ViegiG, BrusascoV, CrapoRO, BurgosF, CasaburiR, et al. Interpretative strategies for lung function tests. Eur Respir J, 2005; 26(5):948-968.
9.
Enright MdP. Office-based DLCO tests help pulmonologists to make important clinical decisions. Respir Investig, 2016; 54(5):305-311.
10.
KeoghBA, CrystalRG. Clinical significance of pulmonary function tests. Pulmonary function testing in interstitial pulmonary disease. What does it tell us?. Chest, 1980; 78(6):856-865.
11.
Du PlessisJP, FernandesS, JamalR, CampP, JohannsonK, SchaefferM, et al. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. Respirology, 2018; 23(4):392-398.
12.
MarciniukDD, WattsRE, GallagherCG. Dead-space loading and exercise limitation in patients with interstitial lung disease. Chest, 1994; 105(1):183-189.
13.
SchaefferMR, RyersonCJ, RamsookAH, Molgat-SeonY, WilkieSS, DhillonSS, et al. Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. Eur Respir J, 2018; 51(1):1701726.
14.
SchaefferMR, GuenetteJA, RamsookAH, Molgat-SeonY, MitchellRA, WilkieSS, et al. Qualitative dimensions of exertional dyspnea in fibrotic interstitial lung disease. Respir Physiol Neurobiol, 2019; 266:1-8.
15.
KaminskyDA, WhitmanT, CallasPW. DLCO versus DLCO/VA as predictors of pulmonary gas exchange. Respir Med, 2007; 101(5):989-994.
16.
NederJA, BertonDC, MullerPT, O’DonnellDE. Incorporating lung diffusing capacity for carbon monoxide in clinical decision making in chest medicine. Clin Chest Med, 2019; 40(2):285-305.
17.
KraussE, van der BeckD, SchmalzI, WilhelmJ, TelloS, DartschRC, et al. Evaluation of regional pulmonary ventilation in spontaneously breathing patients with idiopathic pulmonary fibrosis (IPF) employing electrical impedance tomography (EIT): a pilot study from the European IPF Registry (eurIPFreg). J Clin Med, 2021; 10(2):192.
18.
AgustíAG, RocaJ, GeaJ, WagnerPD, XaubetA, Rodriguez-RoisinR. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis, 1991; 143(2):219-225.
19.
HansenJE, WassermanK. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest, 1996; 109(6):1566-1576.
20.
PanagiotouM, ChurchAC, JohnsonMK, PeacockAJ. Pulmonary vascular and cardiac impairment in interstitial lung disease. Eur Respir Rev, 2017; 26(143):160053.
PanagiotouM, PolychronopoulosV, StrangeC. Respiratory and lower-limb muscle function in interstitial lung disease. Chron Respir Dis, 2016; 13(2):162-172.
23.
Molgat-SeonY, GulerSA, PetersCM, VasilescuDM, PuyatJH, CoxsonHO, et al. Pectoralis muscle area and its association with indices of disease severity in interstitial lung disease. Respir Med, 2021; 186:106539.
24.
MarillierM, BernardA-C, VergesS, Moran-MendozaO, NederJA. Quantifying leg muscle deoxygenation during incremental cycling in hypoxemic patients with fibrotic interstitial lung disease. Clin Physiol Funct Imaging. 2023; 43(3):192-200.
25.
MarillierM, BernardA-C, VergesS, Moran-MendozaO, O’DonnellDE, NederJA. Oxygen supplementation during exercise improves leg muscle fatigue in chronic fibrotic interstitial lung disease. Thorax, 2021; 76(7):672-680.
26.
MarillierM, BernardA-C, VergesS, Moran-MendozaO, O’DonnellDE, NederJA. Influence of exertional hypoxemia on cerebral oxygenation in fibrotic interstitial lung disease. Respir Physiol Neurobiol, 2021; 285:103601.
27.
FaisalA, AlghamdiBJ, CiavagliaCE, ElbehairyAF, WebbKA, OraJ, et al. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. Am J Respir Crit Care Med, 2016; 193(3):299-309.
28.
MilneKM, Ibrahim-MasthanM, ScheerenRE, JamesMD, PhillipsDB, Moran-MendozaO, et al. Inspiratory neural drive and dyspnea in interstitial lung disease: effect of inhaled fentanyl. Respir Physiol Neurobiol, 2020; 282:103511.
29.
WilleMMW, ThomsenLH, PetersenJ, de BruijneM, DirksenA, PedersenJH, et al. Visual assessment of early emphysema and interstitial abnormalities on CT is useful in lung cancer risk analysis. Eur Radiol, 2016; 26(2):487-494.
30.
HallGL, FilipowN, RuppelG, OkitikaT, ThompsonB, KirkbyJ, et al. Official ERS technical standard: global lung function initiative reference values for static lung volumes in individuals of European ancestry. Eur Respir J, 2021; 57(3):2000289.
31.
QuanjerPH, StanojevicS, ColeTJ, BaurX, HallGL, CulverBH, et al. ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J, 2012; 40(6):1324-1343.
32.
StanojevicS, GrahamBL, CooperBG, et al. Global Lung Function Initiative TLCO working group; Global Lung Function Initiative (GLI) TLCO. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J, 2020; 56(4):1750010.
33.
GuenetteJA, ChinRC, CoryJM, WebbKA, O’DonnellDE. Inspiratory capacity during exercise: measurement, analysis, and interpretation. Pulm Med, 2013; 2013:956081.
34.
NederJA, PhillipsDB, O’DonnellDE, DempseyJA. Excess ventilation and exertional dyspnoea in heart failure and pulmonary hypertension. Eur Respir J, 2022; 60(5):2200144.
35.
NederJA, BertonDC, ArbexFF, AlencarMC, RochaA, SperandioPA, et al. Physiological and clinical relevance of exercise ventilatory efficiency in COPD. Eur Respir J, 2017; 49(3):1602036.
36.
NederJA, BertonDC, PlachiF, PhillipsD, SmythR, JamesM. Submaximal breathing reserve during incremental cycle ergometry: reference values and clinical validation. European Respiratory Journal, 2022; 60(Suppl 66).
37.
NederJA, BertonDC, NeryLE, TanWC, BourbeauJ, O’DonnellDE. A frame of reference for assessing the intensity of exertional dyspnea during incremental cycle ergometry. Eur Respir J, 2020:2000191.
38.
RiesAL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg scale, and visual analog scale. COPD, 2005; 2(1):105-110.
39.
NederJA, SmythRM, PhillipsDB, JamesMD, VincentSG, MilneKM, et al. Why patients with lung fibrosis showing only mild restriction at rest may develop limiting dyspnoea on exertion?. European Respiratory Journal, 2022; 60(Suppl 66).
40.
HughesJMB. The single-breath transfer factor (Tl,co) and the transfer coefficient (Kco): a window onto the pulmonary microcirculation. Clin Physiol Funct Imaging, 2003; 23(2):63-71.
41.
DavisC, SheikhK, PikeD, SvenningsenS, McCormackDG, O’DonnellD, et al. Canadian Respiratory Research Network. Ventilation heterogeneity in never smokers and COPD: comparison of pulmonary functional magnetic resonance imaging with the poorly communicating fraction derived from plethysmography. Acad Radiol, 2016; 23(4):398-405.
42.
MacklemPT. The physiology of small airways. Am J Respir Crit Care Med, 1998; 157(5 Pt 2):S181-183.
43.
IkezoeK, HackettT-L, PetersonS, PrinsD, HagueCJ, MurphyD, et al. Small airway reduction and fibrosis is an early pathologic feature of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2021; 204(9):1048-1059.
44.
NederJA. Residual exertional dyspnea in cardiopulmonary disease. Ann Am Thorac Soc, 2020; 17(12):1516-1525.
45.
DempseyJA, NederJA, PhillipsDB, O’DonnellDE. The physiology and pathophysiology of exercise hyperpnea. Handb Clin Neurol, 2022; 188:201-232.
46.
RobertsonHT. Dead space: the physiology of wasted ventilation. Eur Respir J, 2015; 45(6):1704-1716.
47.
WhippBJ. Control of the exercise hyperpnea: the unanswered question. Adv Exp Med Biol, 2008; 605:16-21.
48.
WhippBJ. The hyperpnea of dynamic muscular exercise. Exerc Sport Sci Rev, 1977; 5:295-311.
49.
PeterssonJ, GlennyRW. Gas exchange and ventilation-perfusion relationships in the lung. Eur Respir J, 2014; 44(4):1023-1041.
50.
NederJA, KirbyM, SantyrG, PourafkariM, SmythR, PhillipsDB, et al. V̇/Q̇ mismatch: a novel target for COPD treatment. Chest, 2022; 162(5):S0012-3692(22)00577–3.
51.
Van MeerhaegheA, ScanoG, SergyselsR, BranM, De CosterA. Respiratory drive and ventilatory pattern during exercise in interstitial lung disease. Bull Eur Physiopathol Respir, 1981; 17(1):15-26.
52.
MendoncaCT, SchaefferMR, RileyP, JensenD. Physiological mechanisms of dyspnea during exercise with external thoracic restriction: role of increased neural respiratory drive. J Appl Physiol (1985), 2014; 116(5):570-581.
53.
DempseyJA. Respiratory determinants of exercise limitation: focus on phrenic afferents and the lung vasculature. Clin Chest Med, 2019; 40(2):331-342.
54.
BurdonJG, KillianKJ, JonesNL. Pattern of breathing during exercise in patients with interstitial lung disease. Thorax, 1983; 38(10):778-784.
55.
MarillierM, GruetM, BernardA-C, VergesS, Moran-MendozaO, NederJA. The relationship between perceived and performance fatigability in severe fibrotic interstitial lung disease: a prospective, cross-sectional study. ERJ Open Research, in press.
56.
NederJA, SteinR. A simplified strategy for the estimation of the exercise ventilatory thresholds. Med Sci Sports Exerc, 2006; 38(5):1007-1013.
57.
NederJA, BertonDC, MarillierM, BernardA-C, O’DonnellDE. Canadian Respiratory Research Network. Inspiratory constraints and ventilatory inefficiency are superior to breathing reserve in the assessment of exertional dyspnea in COPD. COPD, 2019; 16(2):174-181.
58.
KaminskyDA, JarzembowskiSC. Influence of mouth pressure on measurement of diffusing capacity in the clinical pulmonary function laboratory. Respir Care, 2019; 64(5):576-581.
59.
StanojevicS, KaminskyDA, MillerMR, ThompsonB, AlivertiA, BarjaktarevicI, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J, 2022; 60(1):2101499.
60.
O’DonnellDE, ChauLK, WebbKA. Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. J Appl Physiol (1985), 1998; 84(6):2000-2009.
61.
MarillierM, GruetM, BernardA-C, VergesS, NederJA. The exercising brain: an overlooked factor limiting the tolerance to physical exertion in major cardiorespiratory diseases?. Front Hum Neurosci, 2021; 15:789053.
